Family Med Journals

Family Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Tsertsvadze A et al. – Data primarily from short–term trials (<=12 weeks) indicate that PDE–5 inhibitors were more effective than placebo in improving sexual intercourse success (69.0% vs. 35.0%). The proportion of men with improved erections was significantly greater among those treated with PDE–5 inhibitors (range, 67.0% to 89.0%) than with placebo (range, 27.0% to 35.0%). The PDE–5 inhibitors were associated with increased risk for any adverse events compared with placebo (for example, relative risk with sildenafil, 1.72). In 4 head–to–head RCTs comparing sildenafil, vardenafil, and tadalafil, improvement of ED and adverse events did not differ among treatments. Results from 15 RCTs evaluating hormonal treatment of ED were inconsistent on whether treatment improved outcomes. Evidence was insufficient regarding whether men with ED had a higher prevalence of hypogonadism than men without ED.


Today in Clinical Pharmacology...keeping you current

Olanzapine versus other atypical antipsychotics for schizophrenia
Cochrane Reviews, 03/19/10

Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis
Cochrane Reviews, 03/19/10

Fibrinolytic agents for peripheral arterial occlusion
Cochrane Reviews, 03/19/10


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address